R&D Systems™ Recombinant Human B7-H3 Fc Chimera Protein, CF

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

Manufacturer:  R&D Systems™ 1027B3100

Catalog No. 1027B3100

Description

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED50 for this effect is 3-12 μg/mL. Optimal dilutions should be determined by each laboratory for each application.

Specifications

• Accession Number: NP_079516
• Formulation: Lyophilized from a 0.2 µm filtered solution in PBS.
• Molecular Weight: M.W. (Observed): 70-80 kDa, reducing conditions; M.W. (theoretical): 50 kDa (monomer)
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.
• Source: Mouse myeloma cell line, NS0-derived human B7-H3 protein Human B7-H3 (Leu29-Pro245) (N-terminus) Accession # NP_079516 DIEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Structural Form: Disulfide-linked homodimer
• Gene Symbol: CD276
• Recombinant: Yes
• Protein: B7-H3/CD276

• For Use With (Application): Bioactivity
• Gene ID (Entrez): 80381
• Name: B7-H3 Fc Chimera
• Quantity: 100 µg
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU / 1 µg of the protein by the LAL method.
• Conjugate: Unconjugated
• Reconstitution: Reconstitute at 100 µg/mL in sterile PBS.